As of June 12, 2025, Midatech Pharma PLC (MTPH.L) reports a EV/EBITDA of -92.20.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Midatech Pharma PLC's EV/EBITDA to Peers
To better understand Midatech Pharma PLC's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Midatech Pharma PLC (MTPH.L) | -92.20 |
| Centessa Pharmaceuticals PLC (CNTA) | 1738.84 |
| Genus PLC (GNS.L) | 30.85 |
| Genomed SA (GEN.WA) | 14.20 |
| Plant Advanced Technologies PAT SA (ALPAT.PA) | 13.83 |
| Abcam PLC (ABC.L) | 12.55 |
Compared to its competitors, Midatech Pharma PLC's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.